This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aceragen Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

John Taylor

İcra Kurulu Başkanı

US$444.1k

Toplam tazminat

CEO maaş yüzdesi	17.5%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

John Taylor'un ücretlendirmesi Aceragen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$41m
Dec 31 2022	US$444k	US$78k	-US$23m

Tazminat ve Piyasa: John 'ın toplam tazminatı ($USD 444.06K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 473.78K ).

Tazminat ve Kazançlar: John şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

John Taylor (52 yo)

less than a year

Görev süresi

US$444,062

Tazminat

Mr. John C. Taylor serves as President, Chief Executive Officer and Director since September 28, 2022 at Aceragen, Inc. He was Chief Executive Officer of Spyryx Biosciences, Inc since December 2013 and ser...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Taylor	President	less than a year	US$444.06k	Veri yok
Gwen Thomas	Associate Director of Human Resources	no data	Veri yok	Veri yok
Christina Amendola	Director of Human Resources	no data	Veri yok	Veri yok
Brian Jackey	Senior Vice President of Technical Operations	no data	Veri yok	Veri yok
Deepa Nagpal	Global Head of Quality	no data	Veri yok	Veri yok
Shah Rahimian	Medical Director & Global Clinical Lead for Oncology	no data	Veri yok	Veri yok
Joanna Horobin	Advisor	4.2yrs	US$993.93k	Veri yok
Louis Arcudi	Adviser	no data	US$986.13k	Veri yok

4.2yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: V9Z 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Taylor	President	less than a year	US$444.06k	Veri yok
Michael Dougherty	Independent Director	4.4yrs	US$89.43k	0.26% € 5.3k
Vincent Milano	Chair of the Board of Directors	8.8yrs	US$1.43m	0.10% € 2.0k
Ronald Wooten	Independent Director	less than a year	US$11.88k	Veri yok
Maxine Gowen	Independent Director	7.7yrs	US$66.24k	0% € 0
Cristina Csimma	Independent Director	4.4yrs	US$60.12k	0% € 0
V. Sutton	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Edward Schuchman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Atul Chopra	Member of Scientific Advisor Board	no data	Veri yok	14.31% € 289.2k

4.4yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: V9Z 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

This company listing is no longer active

Aceragen Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Insufficient new directors

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Senior VP & COO recently bought €50k worth of stock

Recent updates

Aceragen Files Form 15

Aceragen, Inc.(NasdaqCM:ACGN) dropped from S&P TMI Index

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought €50k worth of stock

Independent Chairman recently bought €83k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

New 90-day high: €4.48

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

President recently sold €132k worth of stock

New 90-day high: €4.20

New 90-day high: €2.96

Idera Pharmaceuticals, Inc. Announces Board Changes

Revenue in line with expectations

New 90-day high: €2.54

New 90-day high - €2.26

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş